Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 16/20 | 0.64 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.62 |
| ▸ | CDK1 | P06493 | 1/20 | 0.54 |
| ▸ | KDR | P35968 | 1/20 | 0.54 |
| ▸ | PRKCH | P24723 | 1/20 | 0.53 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.53 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.51 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4194592 | 0.92 | PRKCQ (0.76) | PRKCQPRKCDPRKCHPRKCE | |
| SCHEMBL5473022 | 0.90 | PRKCQ (0.65) | PRKCQPRKCDPRKCHPRKCELRRK2 | |
| SCHEMBL4182703 | 0.89 | PRKCQ (0.60) | PRKCQPRKCDPRKCHPRKCE | |
| SCHEMBL4191889 | 0.88 | EGFR (0.57) | PRKCQPRKCDPRKCHPRKCEPDE4B | |
| SCHEMBL4186701 | 0.87 | PRKCQ (0.57) | PRKCQPRKCDCDK1KDRPRKCH | |
| SCHEMBL4196893 | 0.85 | PRKCQ (0.60) | PRKCQPRKCDPRKCHPRKCE | |
| SCHEMBL2985945 | 0.85 | PRKCQ (0.59) | PRKCQPRKCDKDRPRKCHPRKCE | |
| SCHEMBL2980130 | 0.85 | PRKCQ (0.57) | PRKCQPRKCDPRKCHPRKCE | |
| SCHEMBL4185599 | 0.82 | PRKCQ (0.85) | PRKCQPRKCDPRKCHPRKCE | |
| SCHEMBL2983059 | 0.81 | PRKCQ (0.57) | PRKCQPRKCDPRKCHPRKCELRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2027093-A2 | SUBSTITUTED CYANOPYRIDINES AS PROTEIN KINASE INHIBITORS | Wyeth (US) | 2009-02-25 | — | — | EP | claimed |
| WO-2007146323-A2 | SUBSTITUTED CYANOPYRIDINES AS PROTEIN KINASE INHIBITORS | WYETH (US) | 2007-12-21 | — | — | WO | claimed |
| US-20070287738-A1 | Substituted Cyanopyridines as protein kinase inhibitors | WYETH | 2007-12-13 | — | — | US | claimed |
| US-20070287738-A1 | Substituted Cyanopyridines as protein kinase inhibitors | WYETH | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287738-A1 | Substituted Cyanopyridines as protein kinase inhibitors | CNKSR1, MAP3K1, MAP3K6 | PRKCQ 166/4885PRKCD 314/4885CDK1 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.